Eurofins LifeCodexx GmbH – Quality out of Germany Development of innovative and clinical validated non-invasive diagnostic tests Headquartered in Konstanz, Germany, Eurofins LifeCodexx GmbH has been developing innovative and clinically validated non-invasive diagnostic tests based on the newest molecular analytical methods since 2010. With the PrenaTest® launched in 2012, LifeCodexx AG has been changing prenatal diagnostics considerably. The PrenaTest® is Europe’s first non-invasive prenatal test (NIPT) for the determination of the most common chromosomal disorders in unborn children. The test method is based on the analysis of cell-free DNA in the pregnant woman’s blood and can be performed from the ninth month of pregnancy (9+0 p.m.). The PraenaTest® is a safe test that does not present any risks to the unborn child. It determines very accurately whether or not any of the chromosome disorders, such as Down Syndrom, tested are present. If the express service is selected, the waiting time will only be four to six working days. The PraenaTest® may help relieve pregnant women concerns and worries about possible health problems in the child if these are unsubstantiated. The test is performed within Germany in strict conformity with the highest quality standards as per the European Directive on In-vitro Diagnostic Medical Devices. The PrenaTest® is available at select gynecological practices and prenatal diagnostic clinics in various countries throughout Europe, Asia, and the Middle East. In order to find out where the PrenaTest® is available in your country, contact the partners listed or search for the addresses of qualified medical practices and clinics by clicking our practice finder. Visit www.lifecodexx.com for more information Imprint The portal www.lifecodexx.com is a product of LifeCodexx AG. http://lifecodexx.com/en/service/imprint/ LifeCodexx®, PraenaTest® and PrenaTest® are registered trademarks of LifeCodexx AG, Germany.